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Abstract: The prevalence of neuropsychiatric disorders following traumatic brain injury (TBI) is
20%–50%, and disorders of mood and cognition may remain even after recovery of neurologic function
is achieved. Selective serotonin reuptake inhibitors (SSRI) block the reuptake of serotonin in presynaptic
cells to lead to increased serotonergic activity in the synaptic cleft, constituting first-line treatment for
a variety of neurocognitive and neuropsychiatric disorders. This review investigates the utility of SSRIs
in treating post-TBI disorders. In total, 37 unique reports were consolidated from the Cochrane Central
Register and PubMed (eight randomized-controlled trials (RCTs), nine open-label studies, 11 case reports,
nine review articles). SSRIs are associated with improvement of depressive but not cognitive symptoms.
Pooled analysis using the Hamilton Depression Rating Scale demonstrate a significant mean decrease of
depression severity following sertraline compared to placebo—a result supported by several other RCTs
with similar endpoints. Evidence from smaller studies demonstrates mood improvement following SSRI
administration with absent or negative effects on cognitive and functional recovery. Notably, studies on
SSRI treatment effects for post-traumatic stress disorder after TBI remain absent, and this represents an
important direction of future research. Furthermore, placebo-controlled studies with extended follow-up
periods and concurrent biomarker, neuroimaging and behavioral data are necessary to delineate the
attributable pharmacological effects of SSRIs in the TBI population.
Keywords: cognition; depression; meta-analysis; postconcussive disorder; selective serotonin
reuptake inhibitor; sleep disturbance; traumatic brain injury
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1. Introduction
Traumatic brain injury (TBI) is a critical public health concern recognized by the World Health
Organization (WHO) as a leading cause of death and permanent disability worldwide at 10 million
persons annually [1]. TBI contributes to approximately one-third (50,000) of all injury-related
deaths in the United States (U.S.) each year, and 80,000 persons are discharged with TBI-related
impairments [2,3]. While the incidence is 200 per 100,000 persons per year based on emergency
department (ED) admissions, the rate of mild TBI is underestimated and severe TBI is overestimated [4].
In 1993 the American Congress for Rehabilitation Medicine (ACRM) defined mild TBI as loss
of consciousness (LOC) <30 min, Glasgow Coma Scale (GCS) score of 13–15, and posttraumatic
amnesia (PTA) <24 h [5]. Studies have shown that 10% of mild TBI patients continue to suffer from
clinical symptoms at one year post injury [6,7]. Approximately 3.2 million persons in the U.S. live
with long-term TBI-related disability [8]. Disorders of mood, arousal, attention, anxiety, and sleep
disturbances are widely reported following TBI, presenting during both the initial stages of injury
and the post-acute continuum of recovery. Psychiatric and emotional sequelae can persist even after
neurologic function returns. While the true prevalence of these disorders is difficult to determine due
to selection/reporting biases, the correlation between TBI and the development of neuropsychiatric
disorders is well documented at 40%–48% and 23%–29% respectively [9,10]. These post-TBI sequelae
in inpatient and outpatient settings remain difficult to manage clinically, exacerbating functional
disability, perception of impairment, and effectiveness of rehabilitation.
One unifying mechanism underlying acquired neuropsychiatric conditions following TBI is
disruption of the serotonergic system. Serotonin is an indolamine neurotransmitter with cell bodies
located primarily in the caudal raphe nuclei of the medulla with projections to the cerebellum and spinal
cord, and the rostral raphe nuclei in the pons supplying the prefrontal cortex, forebrain, limbic-striatal
system, hippocampus, and cerebellum [11]. Genetic polymorphisms in coding regions for serotonin
receptors and transporters have been implicated in depression, drug abuse, schizophrenia, aggression,
and Alzheimer’s disease [12,13]. As serotonin cannot cross the blood-brain barrier, synthesis must
occur de novo in the brain. During TBI the shearing of brainstem axons effectively disrupts pontine
and medullary serotonergic projections, resulting in the decreased production and metabolism of
serotonin [14–17].
Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant agents that inhibit
the reuptake of serotonin by monoamine transporters in the presynaptic cell, allowing for increased
availability of serotonin in the synaptic cleft and increased/repeated stimulation of serotonergic
postsynaptic receptors, leading to increased synaptic signaling. SSRIs are indicated for the treatment of
psychiatric disorders including depression, obsessive-compulsive disorder, bulimia, and panic disorder
through the modulation of neuronal cell survival and neuroplasticity. SSRIs increase extracellular
serotonin (5-HT), activating the seven types of 5-HT receptors and many subtypes of each class, which
can also be directly stimulated by the SSRI. Biomolecular benefits are the upregulation of transcription
factor cAMP-responsive element binding protein (CREB) [18], brain-derived neurotrophic factor
(BDNF) production [19], astrocyte glycogenolysis for energy supply [20], and inhibition of neurotoxicity
and apoptosis [21,22]. In the management of neurodegenerative diseases—Alzheimer’s disease,
Parkinson’s disease, stroke, Huntington’s disease, multiple sclerosis, and epilepsy—the benefits of
SSRIs have been reported in small clinical studies. In the larger TBI population, irreversible damage to
neurons result in substantial psychosocial dysfunction and post-concussive symptomatology, which in
theory can be modulated by SSRIs through optimization of the neuronal metabolism and neurotrophic
factors. A hallmark antidepressant effect begins at three to four weeks following administration and
adherence is recommended for at minimum three to six months [23].
Serotonin modulates mood, arousal, emotion, and working memory among other states
and/or symptomatologies, and therefore SSRIs constitute an attractive, titratable, and potentially
long-term pharmacological intervention for post-TBI neurocognitive and neuropsychiatric deficits.
Animal models have demonstrated the effectiveness of SSRIs in treating a range of neurological
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disorders [24]. In humans, evidence-based knowledge of the optimal management of psychiatric
impairment —both temporary and permanent—in neurodegenerative disorders and following TBI
have mainly emphasized upon reducing depression symptomatology with promising results. However,
the management on other common neuropsychiatric disorders following TBI has been a challenge
to investigate and exist in separate reports. In the current article, we comprehensively review and
evaluate the evidence to date on SSRI treatment effects for the spectrum of post-TBI outcome domains
including depression, cognition, post-concussive symptoms/syndrome, sleep disturbance, anxiety,
and post-traumatic stress disorder (PTSD).
2. Methods
2.1. Study Selection
The initial literature search was performed using the Cochrane Central Register for Controlled
Trials (CENTRAL) with the following search criteria: [“traumatic brain injury (ti, ab, kw)” and
((“selective serotonin reuptake inhibitor (ti, ab, kw)” or “citalopram (ti, ab, kw)” or “escitalopram
(ti, ab, kw)” or “fluvoxamine (ti, ab, kw)” or “fluoxetine (ti, ab, kw)” or “paroxetine (ti, ab, kw)” or
“sertraline (ti, ab, kw)”))] through 15 September 2016. A total of 13 original studies were identified.
A second literature search was performed using the National Library of Medicine (NLM) PubMed
database for all English language manuscripts matching the following criteria: [(traumatic brain injury
[title/abstract, MESH terms]) and ((selective serotonin reuptake inhibitor [title/abstract, MESH terms]
or citalopram [title/abstract, MESH terms] or escitalopram[title/abstract, MESH terms] or fluvoxamine
[title/abstract, MESH terms] or fluoxetine[title/abstract, MESH terms] or paroxetine[title/abstract,
MESH terms] or sertraline[title/abstract, MESH terms]))]. A total of 83 manuscripts were identified
from NLM PubMed, of which seven manuscripts overlapped with CENTRAL search.
Three study authors (J.K.Y., J.F.B., P.S.U.) independently reviewed each article and its
accompanying references for scientific merit, with focus on use of SSRI as a therapeutic intervention
after TBI, and reached consensus regarding the inclusion of each reference into the current review. Any
disagreements were adjudicated independently by the senior author (P.E.T.).
Of the 89 unique articles identified, 52 were removed due to lack of applicability to the current
review (17 did not define TBI as the study population of interest, 14 were animal studies, 10 did not
discuss SSRI as a treatment modality, five were pediatric studies, three were non-English language,
two were repeated studies, and one was an internet article). A final total of 37 manuscripts (eight
randomized-controlled trials (RCT), nine open-label studies, 11 case reports, nine review articles) were
deemed fit for inclusion as part of the current review (Figure 1; Table 1).
Finally, manuscripts were assessed for the common endpoint of depression. The Hamilton
Depression Rating Scale (Ham-D) [25] was the only common outcome measure across multiple studies
and was therefore selected as the endpoint for our meta-analysis.
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Table 1. Summary of studies.
Randomized-Controlled Trials
Author Treatment Description N Endpoints Results Post-TBI Disorder
Ansari et al.,
2014 [26] Sertraline
80 adult male patients with post-TBI
depression. 40 patients given sertraline
50 mg/day, 40 patients given placebo.
80 PHQ-9
Sertraline group showed significant improvement in
mood and QOL domains (PHQ-9: 14.88 ± 3.60 vs.
5.33 ± 2.98, p = 0.040).
Depression
Ashman et al.,
2009 [27] Sertraline
10-week program studying 52 patients with
TBI and MDD treated with sertraline or
placebo.
52 Ham-D Both groups significantly improved (59% treatment group,32% placebo group) with Ham-D reduction by 50%. Depression
Banos et al.,
2010 [28] Sertraline
Three-month study of 99 subjects with
moderate/severe TBI randomized to
sertraline 50 mg (n = 49) or placebo (n = 50).
99 WMS, TMT,NFI
No sertraline treatment effect was observed for
cognitive performance. Cognition
Jorge et al.,
2016 [29] Sertraline
94 patients administered sertraline vs.
placebo at 100 mg/day for 24-weeks. 94 MINI
Number needed to treat to prevent depression after TBI at
24-weeks is 5.9 for sertraline vs. placebo (p = 0.03).
Sertraline effects were well-tolerated.
Depression
Lee et al., 2005
[30] Sertraline
Four-week study of 30 patients with MDD
treated with sertraline 25–100 mg/day
(n = 10), methylphenidate 5–20 mg/day
(n = 10), or placebo (n = 10).
30 Ham-D, ESS,RPQ
Methylphenidate and sertraline showed improvement
in depressive symptomatology. Methylphenidate and
placebo showed improvement in cognitive
function vs. sertraline.
Cognition,
Depression, PCS
Meythaler et al.,
2001 [31] Sertraline
Two-week study of 11 patients with severe
TBI post MVA. Patients received sertraline
100 mg/day or placebo.
11 OL, ABS,GOAT No effect of sertraline treatment was identified. Cognition
Novack et al.,
2009 [32] Sertraline
One-year study of 99 non-depressed TBI
subjects received either sertraline 50
mg/day (n = 49) or placebo (n = 50).
99 Ham-D, NFI
Placebo group developed more depressive symptoms
(p = 0.023). Sertraline associated with decreased
neurobehavioral functioning.
Depression
Rapoport et al.,
2010 [33] Citalopram
21 patients in remission from depression
after TBI were randomized to same-dose
citalopram (n = 10) or placebo (n = 11) and
followed for 40 weeks.
21 Ham-D
Relapse occurred in 11 subjects (52.4%). Treatment groups
did not differ in relapse rates (citalopram: 50% vs.
placebo: 54.5%; p = 0.835). This trial suggested limitations
of pharmacotherapy in the prevention of MDD relapse
following TBI.
Depression
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Table 1. Cont.
Open-Label Studies
Author Treatment Description N Endpoints Results Post-TBI Disorder
Dolberg et al.,
2002 [34]
Fluoxetine,
Citalopram,
Paroxetine,
Sertraline
17 TBI patients were given SSRIs. All
complained of sexual dysfunction which
was resolved with mianserin (tetracyclic
anti-depressant).
17
Occurrence of
sexual
dysfunction
SSRI use associated with sexual dysfunction. 15 patients
(88%) reported improvement of symptoms with
mianserin.
Sexual
dysfunction
Fann et al.,
2000 [35] Sertraline
15 patients with mild TBI within the past
3–24 months. Placebo in-run design where
all subjects received 1-week placebo
followed by 8-week single-blind course
of sertraline.
15 Ham-D
Sertraline significantly improved depressive symptoms
(Ham-D 25.0 ± 4.4 to 7.2 ± 5.3 at Week 8 (p < 0.001). There
was improvement of cognitive functions in psychomotor
speed, cognitive efficiency, flexible thinking, and recent
memory ability.
Cognition,
Depression
Horsfield et al.,
2002 [36] Fluoxetine
5 TBI patients with no to moderate
depressive symptoms followed for
8 months.
5
TMT, AMT,
WAIS-III,
USCREMT,
MMSE,
Ham-D
Fluoxetine improved mood and performance on some but
not all cognitive measures. More studies needed. Cognition
Lanctot et al.,
2010 [37] Citalopram
90 patients with major depressive episode
following TBI in a six week study also
examining six serotonergic SNPs.
90 Ham-D
MTHFR and BDNF SNPs predicted greater treatment
response (r2 = 0.098, F = 4.65, p = 0.013). The 5HTTLPR
SNP predicted greater occurrence of adverse events
(r2 = 0.069, F = 5.72, p = 0.020). Serotonergic SNPs may
associate with tolerability and efficacy of SSRIs.
Depression
Luo et al., 2015
[38]
Citalopram,
prednisone 68 patients with depression following TBI. 68
Glasgow
Coma Scale,
Ham-D
Over 60% of patients who did not respond to
psychotherapy alone (60/68) responded to citalopram
treatment. Patients with hypocortisolism also were treated
with prednisone
Depression
Muller et al.,
1999 [39]
Paroxetine,
Citalopram
26 patients with brain damage and
pathological crying. Only 2 TBI related. 2
Clinical
interviews
related to
pathological
crying
Both paroxetine and citalopram improved symptoms for
24/26 (92.3%) patients within 3 days.
Emotional
incontinence
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Table 1. Cont.
Open-Label Studies
Author Treatment Description N Endpoints Results Post-TBI Disorder
Perino et al.,
2001 [40]
Citalopram,
Carbamazepine
20 patients with MDD following TBI were
divided into two groups: group A with
recent TBI (<6 months), and group B with
long-term TBI (24–36 months).
20 BPRS
BPRS and CGI scores of the total sample showed significant
improvement between baseline and 12 weeks (BPRS
baseline: 62.3 ± 17.6 vs. 12 weeks: 51.7 ± 12.8; p < 0.05),
(CGI severity-scale baseline: 4.4 ± 1.1 vs. 12 weeks:
3.4 ± 0.8; p < 0.005). No group effects were observed.
Depression
Rapoport et al.,
2008 [41] Citalopram
54 patients with mild to moderate
depression post-TBI. 29 patients underwent
6 week fixed dose treatment; 36 underwent
10-week flexible dose treatment.
54 Ham-D
The mean Ham-D at baseline and 6 weeks were 23.66
(SD 6.8) and 16.30 (SD 9.3), respectively (p < 0.0001).
The mean Ham-D at 10 weeks was 12.96 (SD 7.9)
(p < 0.0001). Treatment showed significant reduction in
depressive symptoms.
Depression, PCS
Turner-
Stokes et al.,
2002 [42]
Sertraline 27 patients with depression due to braininjury - 5 due to TBI. 27 BDI-II
The BDI-II was assessable in 17/21 patients, showing
a mean improvement of 14.5 ± 9.7 (p < 0.001). Depression
Case Reports
Author Treatment Description N Endpoints Results Post-TBI Disorder
Hensley et al.,
2010 [43]
Sertraline,
Paroxetine 22-year-old female with MVA-related TBI. 1 –
Treatment of alcohol withdrawal related anxiety with
SSRIs led to akathisia that resolved with TCA treatment.
Akathisia,
Anxiety
Nahas et al.,
1998 [44] Fluoxetine
21-year-old male with MVA-related TBI
leading to pathological crying. 1 –
Fluoxetine treatment led to complete resolution of
pathological crying within 1 week.
Emotional
incontinence
Patterson et al.,
1997 [45]
Sertraline,
Trazodone
43-year-old male with TBI following fall
prescribed trazodone for chronic pain and
sleep disturbance, and fluoxetine for
treatment of depression.
1 – Fluoxetine addition led to dysarthria that resolved withfluoxetine discontinuation. Depression
Scheutzow et al.,
1999 [46] Sertraline
60-year-old male with TBI following MVA
experiencing panic attacks. 1 –
Sertraline improved mood and appetite but did not
resolve all panic and anxiety symptoms. Anxiety, Panic
Slaughter et al.,
1999 [47] Sertraline
2 male patients with Kluver-Bucy syndrome
from MVA related TBI. 2 –
Resolution of symptoms (hyperorality, hyper-sexuality)
with high dose SSRI similar to OCD.
Emotional
incontinence,
OCD
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Table 1. Cont.
Case Reports
Author Treatment Description N Endpoints Results Post-TBI Disorder
Sloan et al.,
1992 [48] Fluoxetine
28-year-old assault victim with TBI related
pathological laughter, dysarthria
and hemiataxia.
1 – Fluoxetine plus speech therapy helped with emotionallability grading and was well tolerated.
Emotional
incontinence
Spinella et al.,
2002 [49]
Fluoxetine,
Buspirone,
Ginkgo
Biloba
42-year-old female with mild TBI
following MVA. 1 –
Herbal supplements plus SSRI led to hypomania,
highlighting the need to study SSRI interactions with
other medications following TBI.
Depression
Stanislav et al.,
1999 [50] Sertraline
24-year-old with severe TBI following MVA
presenting with PTSD. 1 – Clinical case of dystonia following SSRI treatment. Depression, PTSD
Stengler-
Wenzke et al.,
2002 [51]
Fluoxetine 18-year-old male with severe TBIfollowing MVA. 1 –
Fluoxetine treatment drastically reduced OCD symptoms
and increased quality of life. OCD
Workman et al.,
1992 [52]
Sertraline,
Lithium
56-year-old female with severe TBI from fall
requiring bilateral frontal lobectomies. 1 –
Sertraline plus lithium treatment reduced patients Ham-D
score from 15 to 4. Symptoms of mood lability and
conceptual disorganization resolved.
Emotional
incontinence
Wroblewski et al.,
1992 [53]
Fluoxetine,
Phenytoin
23-year-old TBI patient with seizures
following TCA treatment of depression. 1 –
Resolution of seizures and improvement of mood with
fluoxetine treatment with phenytoin. Depression
Review Articles
Author Treatment Description N Endpoints Results Post-TBI Disorder
Fann et al.,
2009 [54] Review – – –
Serotonergic system modulation through antidepressants
has high tolerability in treatment of TBI patients
with depression.
General
Fleminger et al.,
2003 [55] Review – – –
Three- to four-fold increase in suicide rates following TBI,
suggested heightened surveillance for TBI subpopulations.
Little conclusive evidence for SSRI use highlights need for
longitudinal care.
Depression
Jorge et al.,
2003 [56] Review – – –
Mood disorders are frequent complications of TBI and are
often overlooked. Further research is needed for the
neuropsychiatric sequelae of these disorders.
Anxiety, OCD,
Panic
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Table 1. Cont.
Review Articles
Author Treatment Description N Endpoints Results Post-TBI Disorder
Lee et al., 2003
[57] Review – – –
Up to 60% of TBI patients are affected by neuropsychiatric
sequelae. Drugs exist to treat specific conditions but RCTs
are needed to delineate true treatment effects
following TBI.
Anxiety,
Cognition,
Depression
Lombardi et al.,
2008 [58] Review – – –
Symptomatic treatment studies that understand and
address underlying neurobiological recovery processes
are needed.
Cognition, PCS
Silver et al.,
2009 [59] Review – – –
Depression and cognitive impairment are common
neuropsychiatric symptoms after TBI. Several small
studies suggest that SSRIs and tricyclic antidepressants
may improve depression in this population.
Cognition,
Depression
Tenovuo et al.,
2006 [60] Review – – –
Lack of large scale RCTs place burden on clinician for
pharmacologic treatment of TBI-related depression. Cognition
Wheaton et al.,
2011 [61] Review – – –
Pharmacological treatments that are administered to
adults in the postacute stage (≥4 weeks) after TBI have
the potential to reduce persistent cognitive and behavioral
problems. Sertraline can possibly impair cognition and
psychomotor speed.
Cognition
Zafonte et al.,
2002 [23] Review – – –
Limited studies exist among patients with TBI, but
serotonin agents including SSRIs seem to be effective for
a variety of behavioral disorders. Care should be used
when combining agents, and rapid withdrawal should
be avoided.
Anxiety,
Cognition,
Depression
ABS = Agitated Behavioral Scale; AMT = attentional motor task; BDI-II = Beck Depression Inventory, Second Edition; BPRS = Brief Psychiatric Rating Scale; ESS = Epworth Sleepiness Scale;
GCS = Glasgow Coma Scale; Ham-D = Hamilton Depression Rating Scale; GOAT = Galveston Orientation and Amnesia Test; MDD = major depressive disorder; MINI = Mini-International
Neuropsychiatric Interview; MMSE = Mini-Mental State Examination; MVA = motor vehicle accident; NFI = Neurobehavioral Functioning Inventory; OCD = Obsessive Compulsive
Disorder; OL = Orientation Log; PHQ-9 = Patient Health Questionnaire-9; RPQ = Rivermead Post-Concussional Symptoms Questionnaire; SNP = single nucleotide polymorphism;
SSRI = selective serotonin reuptake inhibitor; TBI = traumatic brain injury; TCA = tricyclic antidepressant; TMT = Trailmaking Test; USCREMT = University of Southern California
Repeatable Episodic Memory Test; WAIS-III = Wechsler Adult Intelligence Test, Third Edition; WMS = Wechsler Memory Scale.
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Figure 1. Flowchart of included studies. CENTRAL, Cochrane Central Register for Controlled Trials;
SSRI, selective serotonin reuptake inhibitor; TBI, traumatic brain injury.
2.2. Statistical Analysis
For studies included in the meta-analysis, standard deviations and mean Ham-D values before
and after intervention for both placebo and sertraline groups were recorded. ithin each treatment
group (sertraline, placebo) mean differences in Ham-D score was calculated using mpre − mpost and
pooled standard deviations of the standard mean difference was calculated using sqrt(((n− 1)× SDpre +
(n− 1)× SDpost)÷ (2n + 2)) , where m re , SDpre are the mean and standard deviation pre-intervention
and post, SD ost are the ean and standard deviation post-treat ent. The standardized ean
difference, pooled standard deviation and sa ple size values for the intervention and placebo groups
of each study were entered into the R statistical package AVIS ( eta-Analysis via Shiny) R-Shiny
application [62]. Hedge’s g, a standardized easure of the nu ber of standard deviations the control
and treat ent eans differ by, is reported for the meta-analysis as an unbiased measure of effect
size [63].
3. Results
3.1. Depression
3.1.1. Background and Pathophysiology
Serotonergic neuronal projections modulate mood and play a central role in depression
symptomatology [64]. Jarring movement from traumatic injury often causes the brain to strike
against the anterior fossae leading to damage of anterior frontal lobe neuronal networks, which are
heavily innervated by serotonergic projections from the raphe nuclei [65]. Most neurotransmitter
concentrations normalize within a matter of days but chronic deficits in serotonergic, dopaminergic,
cholinergic and adrenergic systems cause persistent neuropsychiatric sequelae. The incidence for
post-TBI depression ranges from 6% to 77% due to variable diagnostic standards [56], and up to 53%
in the first year post injury [66]. Standard treatments include pharmacotherapy, of which SSRIs are
first-line, and cognitive behavioral therapy (not included in the current review) [59]. Consequently,
judicious use of SSRIs in the management of post-TBI depression is of high importance and impact.
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3.1.2. Evidence Synthesis: Sertraline
Sertraline is the most-often investigated SSRI in post-TBI depression, possibly due to improved
understanding of its interaction with cytochrome P450 (CYP450) enzymes for metabolism compared
to other SSRIs [59]. Five RCTs, two open-label studies, and two case reports investigate the use of
sertraline to treat depression.
Regarding the potential of early prophylaxis for depression, e.g., the reduction of depression
incidence and/or symptoms from administration of SSRI relatively soon after suffering TBI, Novack
and colleagues randomized 99 moderate to severe TBI patients without baseline antidepressant use
or drug abuse to sertraline 50 mg/day (n = 49) vs. placebo (n = 50) for one year. Eligible patients
were enrolled no more than eight weeks following TBI, and treatment (sertraline vs. placebo) was
started on the day after enrollment. No sertraline-treated patients developed depression assessed by
the Ham-D Short Form. However, patients on sertraline scored poorer on the depression subscale of
the Neurobehavioral Functioning Inventory (NFI), which is an overall an 83-item self-report inventory
quantifying symptoms and behaviors associated with acquired neurological injury across six domains
(depression, somatic complaints, memory/attention difficulties, communication deficits, aggressive
behaviors, motor impairment), compared to placebo at three months. No significant differences were
found between three-month and 12-month scores for either Ham-D or NFI [32].
Another large recent double-blind RCT performed by Jorge and colleagues attempts to address
the utility of sertraline for prophylaxis following TBI. In 94 adult patients suffering mild to severe TBI
without ongoing baseline depression or mood disorders, and with complete recovery of posttraumatic
amnesia within four weeks of injury, were administered sertraline or placebo at the dose of 25 mg/day
for the first five days, 50 mg/day for the next five days, and 100 mg/day thereafter [29]. Diagnosis of
depression was performed using the Mini-International Neuropsychiatric Interview and the Diagnostic
and Statistical Manual for Mental Disorders, Fourth Edition (DSM-IV) criteria at 2-, 4-, 8-, 12-, 16-, 20-
and 24-week in-person follow-up visits, as well as telephone visits at weeks 6, 10, 14, 18, and 22. The
authors found that the number needed to treat (NNT) to prevent depression after TBI at 24-weeks was
5.9 persons (e.g., on average, 5.9 patients will need to undergo treatment for one case of depression to
be prevented). Sertraline patients were more likely to experience dry mouth and diarrhea, however
neither sexual side effects nor suicidal ideation were attributable to sertraline administration [29].
Ashman and colleagues conducted a 10-week double blind RCT with 52 TBI subjects suffering
from major depressive disorder (MDD) by DSM-IV criteria [27]. Patients were started on sertraline
25 mg/day for one to two weeks followed by dose adjustment up to 100 mg/day. Medications were
reassessed at two-week intervals and treatment responders were quantified by a 50% drop in Ham-D
score, or a final Ham-D score of below 10. Treatment response rate was 59% compared to 32% for
placebo. The authors noted a significant time effect for improvement of depression in both groups, and
time as a confounder illustrates the inherent challenge in delineating the magnitude of SSRI treatment
effect versus the natural course of mood recovery following TBI [27].
Lee and colleagues conducted a four-week double-blind parallel group trial with three treatment
arms: placebo, sertraline (25–100 mg/day), and methylphenidate (2.5–20 mg/day) [30]. Thirty subjects
with mild to moderate TBI injured between two weeks to one year previously who met DSM-IV
criteria for MDD were randomized. Post-hoc analysis adjusting for group and time effects found that
both sertraline and methylphenidate significantly improved depressive symptoms as assessed by the
Ham-D and Beck Depression Index (BDI). Sertraline was associated with a higher rate of adverse
events, and decreased performance on several cognitive tasks, compared to methylphenidate and
placebo. The ambiguity of these results and the potential for side effects show that the treatment
of depression and other behavioral outcomes with SSRIs in the TBI population continue to require
large-scale RCTs to become generalizable [57].
An RCT focused on depression and quality of life (QoL) was conducted by Ansari and colleagues
in 80 male patients with post-TBI depression randomized to sertraline or placebo, with sertraline
showing significant improvement in depressive symptoms and QoL at three, six and nine months.
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Interestingly, patients suffering left-sided brain injury were more prone to developing post-TBI
depression in this cohort [26].
Perino and colleagues conducted a prospective cohort study of 20 post-TBI patients with
major depression diagnosed by two neuropsychiatrists from a group of 37 consecutive TBI patients
undergoing counseling [40]. The patients were classified by time elapsed from trauma (Group A,
<6 months; Group B, 24–36 months) and received combination therapy of carbamazepine 600 mg/day
and sertraline 20 mg/day for 12 weeks. Carbamazepine is an anticonvulsant known to temper volatile
mood. The brief psychiatric rating scale (BPRS) and the clinical global impression scale were recorded
at baseline and after 12 weeks. Both the brief psychiatric rating scale and the clinical global impression
outcomes showed statistically significant improvement in all patients, although Group B did not
recover as well as Group A. Thought disorganization, depression, and psychomotor retardation
showed the highest magnitude of improvement [40].
Fann and colleagues conducted a nine-week, nonrandomized single-blind trial of sertraline
in 15 patients with MDD 3–24 months after mild TBI. Patients received placebo in week zero to
eliminate “placebo responders”, and were dosed with 25–150 mg/day sertraline in the following
eight weeks. Thirteen patients improved their overall Ham-D score by 50% and 10 demonstrated
full remission with low/nonclinical Ham-D scores, indicating sertraline as an effective treatment of
post-TBI depression [35,54].
Turner-Stokes and colleagues assessed response to sertraline in patients with severe disability
following TBI in an integrated care rehabilitation facility. Patients that screened positive for depression
using the BDI were treated for six to eight weeks. Sertraline significantly improved BDI scores even in
patients who had previously been unresponsive to SSRI therapy [42].
3.1.3. Meta-Analysis
Of the included studies in this manuscript, only two were RCTs utilizing the same intervention
(the SSRI sertraline) (Ashman et al., 2009: 22 TBI subjects/19 controls; Lee et al., 2005: 10 TBI
subjects/10 controls) and shared a common endpoint (Ham-D) to qualify for meta-analysis [27,30].
Using the random effects model, a statistically significant pooled effect size difference (Hedge’s g) of
−0.67 (95% CI [−1.19, −0.16]; p = 0.011) was found for sertraline compared with placebo (Figure 2),
demonstrating that sertraline administration following TBI was associated with decreased depression
burden as assessed by Ham-D scores.
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citalopram 20 mg/day, and 36 subjects underwent a six-week trial receiving citalopram on a flexible
dosing schedule of 20–50 mg/day, which was extended to 10-weeks for a subset of individuals. Ham-D
scores improved significantly at six-weeks across the overall cohort, and no statistical difference was
found between scores at six vs. 10 weeks. The authors concluded that flexible dosing and increased
treatment time improved Ham-D scores more than rigid dosing and/or short treatment time [41].
Twenty-one patients who met criteria for remission on the Ham-D following the 10-week treatment
course were subsequently enrolled in a double-blind RCT where 11 patients were given citalopram
and 10 were given placebo. Over 40 weeks of follow-up, no significant difference was noted between
groups in time to relapse or relapse rates (~50%). The fact that nearly half of subjects in the study
experienced relapse suggests increased susceptibility of TBI patients for depressive episodes [67,68].
There is a need to tailor treatment protocols to the time course of recovery and for early intervention,
as response to SSRI has been shown to be most favorable during the subacute phase of recovery [33].
Lanctot and colleagues evaluated six serotonergic SNPs in 90 TBI with MDD diagnosed using
the DSM-IV, including 5-HTT, 5-HT1A, 5-HT2A, TPH2, BDNF, and MTHR [69]. Patients received
20 mg/day of citalopram for six weeks and were assessed using Ham-D pre- and post-treatment.
Patients with a Ham-D decrease of >50% were deemed treatment-responsive. Overall, patients
demonstrated a mean decrease in Ham-D; the percentage of responders and remitters (23%, 17%
respectively) were relatively small, indicating potentially suboptimal treatment doses. BDNF and
MTHR polymorphisms significantly predicted improved treatment outcomes on Ham-D while 5-HTT
polymorphisms predicted greater incidence of adverse effects to treatment [37].
Fleminger and colleagues describe in a review article numerous clinical factors for consideration in
TBI longitudinal care, including the 40% incidence of depression and four-fold increase in suicide rates
compared to the general population [55]. Specifically, a Chinese study highlights the utility of managed
care in 68 patients with clinically diagnosed depression following TBI. After initial psychotherapy,
eight subjects demonstrated remission; remaining subjects were treated with citalopram alone (n = 28),
or citalopram plus prednisone combination due to hypocortisolism (n = 32) [38]. Both groups
demonstrated remission rates >50%. This adds to the evidence base that future studies targeting
combination therapy for individuals suffering post-TBI depression should certainly include SSRIs.
3.1.5. Evidence Synthesis: Fluoxetine
Fluoxetine has been shown to stimulate BDNF expression and potentiate neuronal remodeling
and elongation of CA3 pyramidal neurons in rodent hippocampi, which may lead to improved memory
and executive function. One case report investigated the use of fluoxetine to treat depression. Horsfield
and colleagues investigated five TBI patients with variable severities and depressive symptoms who
were provided fluoxetine on a flexible dosing schedule (20–60 mg/day) for eight months. The authors
found significant improvement on the Ham-D and tests of executive function and mental flexibility
compared to pre-treatment [36].
3.1.6. Commentary
Indications for SSRI to treat depression have been well-studied with a robust evidence base, and
not surprisingly finds concurrence in our review. The narrative of an acute therapeutic window for
SSRI administration in TBI is supported by multiple RCTs and cohort studies [26,27,29,41,54,56,66],
with an estimated reduction ~50% in symptom severity and/or remission rate over the first two to three
months of SSRI administration. It would appear that, at least preliminarily such improvements are
sustained [26,33,54]. There is preliminary evidence suggesting benefit in prophylactic administration of
SSRI in TBI patients without baseline depression, foremost from the RCT by Jorge et al. with a NNT of
5.9 persons treated for one depression case prevented at 24-weeks post injury [29]. However across the
majority of studies, relatively smaller sample sizes, low rates of depression as compared to the overall
TBI population, and inherent challenges in drawing conclusions based on prophylactic studies [32]
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highlight the need for larger RCTs studying the ideal time course for SSRI administration post-TBI in
patients with and without baseline mood disorders.
The inability to clearly separate treatment effect from the natural time course of TBI recovery is
a significant limitation in multiple trials. To this end, a placebo-controlled imaging study examining
functional and/or neurochemical changes during the treatment course can assist in identifying
modulatory changes associated with SSRI [36]. Sample size remains another key issue—although
individually the studies by Lee et al. and Ashman et al. showed no treatment effect for sertraline
versus placebo, when the studies were pooled using a random effects model, a significant pooled effect
size difference of −0.67 was demonstrated between sertraline and placebo. While the limitations of
this meta-analysis include small sample sizes and differing time to follow-up, for the first time there is
pooled preliminary evidence for the benefit of sertraline to treat post-TBI depression.
3.2. Cognition
3.2.1. Background and Pathophysiology
Following mild TBI, memory and information processing faculties are most vulnerable while
language and intellect are relatively well preserved. On average, cognitive deficits resolve one to
three months following mild TBI but can persist in moderate to severe TBI patients for 12 months
or more [70]. While the relationship between TBI, chronic traumatic encephalopathy and dementia
remain in need of further characterization, a number of studies now show that latent cognitive deficits
can surface years after the initial insult [71]. Sixty-three percent of moderate to severe TBI patients
report long-term cognitive impairment and nearly a quarter are unable to return to the workforce.
Although some cognitive deficits can be localized neuroanatomically, the sources of others remain
poorly understood in part due to confounding from behavioral traits.
Cognitive performance is generally measured by task performance on scales e.g., working memory,
verbal fluency, reasoning, judgment, visual construction, and verbal recall [72]. Higher cognitive
functioning is associated with improved life satisfaction, QoL and functional independence [73,74].
The unfavorable cognitive side effect profile of other antidepressant class drugs, such as TCAs
and monoamine oxidase inhibitors (MAOIs), have propelled SSRIs to the forefront of therapeutic
options [59]. Thus, fully understanding the impact of SSRIs on recovery and cognition is critical.
3.2.2. Evidence Synthesis
Ongoing ambiguity exists regarding the impact of SSRIs on cognitive recovery. Three RCTs and
one open-label study investigated the use of sertraline, and one open-label study investigated the
use of fluoxetine, to improve post-TBI cognition. In an RCT by Meythaler and colleagues, 11 severe
TBI patients received sertraline 100 mg/day vs. placebo for two weeks after injury and showed
no significant differences on measures of attention and orientation [31]. In another double-blind
RCT, Baños, Novack and colleagues examined cognitive recovery with early sertraline administration
in 99 patients (sertraline n = 49, placebo n = 50) for three months following TBI. No differences
were observed between the groups on measures of cognitive and executive function as assessed by
the Neurobehavioral Functioning Inventory (NFI) and other standard measures at three, six and
12 months post injury [28,32]. As previously described, Lee and colleagues compared the effects of
sertraline, methylphenidate and placebo on mild-to-moderate TBI patients in a four week double-blind
RCT and demonstrated that the sertraline group performed worse on a number of cognitive tests
including the Mini-Mental Status Exam (MMSE), while the methylphenidate group scored better than
placebo [30]. In a recent meta-analysis, Wheaton and colleagues describe reductions in psychomotor
speed, reaction time and memory attributed to sertraline administration during postacute recovery
from TBI [61]. Interestingly, evidence in cohort studies for SSRI effects has been generally positive.
Fann and colleagues conducted an eight week non-randomized, single-blinded trial for sertraline
3–24 months following mild to moderate TBI, in patients meeting DSM-IIIR criteria for MDD.
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Thirty-two patients were evaluated with a neuropsychiatric battery and across 24 tests, 14 showed
post-treatment improvement including digit symbol, finger-tapping, executive function, memory
recall, visual retention, and self-perception of injury severity. Of importance, the placebo run-in design
of this study mitigates the confounding time effect for natural recovery of cognitive symptoms [75].
A smaller study by Horsfield and colleagues in five TBI patients reported that fluoxetine improved
performance on tests of executive function, attention, and nonverbal intelligence [36].
3.2.3. Commentary
The evidence to date for SSRI effects on cognition is equivocal to detrimental in RCTs, while
cautiously beneficial in select measures of nonverbal cognition in cohort studies. The evidence to
date for SSRI effects on cognition is equivocal to detrimental in RCTs, while cautiously beneficial in
select measures of nonverbal cognition in cohort studies. Murine models have demonstrated that the
neurobiological effects of SSRIs are mediated via hippocampal neurogenesis, whereas irradiation of the
hippocampus-containing region prevents the influence of antidepressants [76–78]. Chronic treatment
using paroxetine appears to improve temporal order memory performance compared to controls [79].
In patients with depression, fluoxetine has been shown to improve memory function without altering
hippocampal volume [80].
The effect of SSRI administration on depression and cognition—two areas of great importance
to the TBI population—are similarly ambiguous. In considering study design, the included studies
lack the adequate time of follow-up necessary to separate drug effects from the natural course of
cerebral and mental health recovery. Although a few studies showed improvement in psychomotor
speed and various attention/memory tasks, no study with a placebo control demonstrated cognitive
improvement attributable to SSRI use. Another consistent limitation is the inability to measure one’s
cognitive function and/or reserve prior to suffering TBI. Notably, the three-group, parallel design
study by Lee et al. demonstrated that while SSRIs led to improvement in depressive symptoms
over the course of the trial, the aggregate cognitive function as assessed by numerous tests was
significantly lower than patients without SSRI treatment. This finding raises important considerations
for the administration of SSRIs post-TBI, as medical professionals struggle to balance the alleviation of
depressive symptoms with the possible worsening of cognitive ability/processing speed. This tradeoff
suggests that SSRIs may benefit specific subpopulations of patients while being a detriment to others.
3.3. Post-Concussive Symptoms/Syndrome
3.3.1. Background and Pathophysiology
Mild TBI comprises 70%–80% of TBI. The constellation of symptoms following TBI, including
headaches, dizziness, irritability, fatigue, depression, and others, are diagnostically and colloquially
termed “post-concussive symptoms”, and if debilitating/disruptive enough to functional, social
and/or cognitive activity, “post-concussive syndrome (PCS)” [81–83]. No FDA-approved treatment
currently exists for PCS [84,85], and options for treating specific symptoms may or may not be beneficial
for treating PCS as a whole. As SSRIs are the first-line treatment for depression—a component of
PCS—it is of interest to assess whether they are indicated in subpopulations of PCS sufferers.
The current standard of measurement for PCS is the Rivermead Post-Concussional Symptoms
Questionnaire (RPQ), assessed three months after TBI [86]. The RPQ consists of 16 self-report symptoms
and a score of “moderate severity” or above in any three symptoms constitutes PCS as assessed by the
DSM-IV [86,87], which has been well validated in mild TBI patients [88–90].
3.3.2. Evidence Synthesis
One RCT investigated the use of sertraline to treat PCS, and one open-label study investigated
the use of citalopram.
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Lee and colleagues conducted a four-week, three-arm RCT (sertraline, methylphenidate, placebo)
in 30 adults following mild-to-moderate TBI and found improved post-study RPQ scores in
both methylphenidate and placebo groups but not in the sertraline group compared to baseline.
One confounder is that the mean baseline RPQ score for the sertraline group was lower than the other
two groups [30].
In a prospective cohort study of 54 patients suffering a major depressive episode or MDD
following mild-to-moderate TBI, Rapoport et al. found a significant mean decrease in RPQ scores
after six weeks of treatment with citalopram 20–50 mg/day, with a treatment response rate of 28% at
six weeks and 42% at 10 weeks. There was no change RPQ score at the end of 10 weeks of treatment
compared to six weeks, suggesting that while citalopram effect persisted, the attenuation of PCS
symptomatology was highest during the subacute phase of recovery [41]. The study shows the
promise for SSRIs as treatment for components of post-concussive symptomatology, however remains
limited by the lack of placebo and of control for concurrent psychotropic medications [41].
3.3.3. Commentary
To date, current data regarding the use of SSRIs to treat PCS are minimal and limited. Part of
the issue stems from the definition of PCS which is heterogeneous consisting of somatic, depressive,
anxiety, and cognitive components. As evidenced in our review, SSRIs have been shown to improve
select symptom clusters, e.g., depression, but remain equivocal to detrimental for others, e.g., cognition.
Hence, further research is needed to identify the subpopulation of PCS patients that would benefit
from SSRI treatment and assess its comparative efficacy and tolerability at different phases of recovery.
In considering combination therapy, it is posited that serotonin inhibits dopaminergic neuronal
projections in the midbrain and forebrain while methylphenidate promotes release and prevents
reuptake of dopamine. Consequently, SSRIs and methylphenidate may have opposing effects in sleep
induction and/or preservation in the context of PCS [91].
As with all TBI studies, heterogeneous cerebral pathophysiologies and severities have hindered
the practical design of large-scale RCTs [58]. Clinicians are often subjected to difficult treatment
decisions, as the small sample sizes and uncontrolled investigation designs of published studies
leaves TBI treatment to clinical practice and experience rather than evidence-based protocol [60].
In considering a complex, multifactorial clinical syndrome such as PCS, first steps toward proper
assessment of SSRI utility and efficacy should be reserved for well-designed, controlled trials targeting
similar TBI subtypes rather than encompassing the spectrum of TBI [57].
3.4. Sleep Disturbance
3.4.1. Background and Pathophysiology
It is estimated that sleep disturbances impact 30%–70% of patients following TBI [92] with
drastic implications on mood and emotional regulation. Sleep disorders often arise from secondary
complications after TBI, and can manifest via sleep apnea, hypersomnia, circadian rhythm disorder,
PTSD, depression, anxiety and pain. The type of sleep disturbance is often associated with the
location of axonal shearing in the brain; damage to the ventrolateral preoptic nucleus, suprachiasmatic
nucleus, basal forebrain and posterior hypothalamus has been associated with sleep disorders in TBI
patients [93]. Correction of sleep disturbance is a critical component of symptom management for TBI
patients [27].
Biochemically serotonin is a precursor to melatonin, a neurohormone with paracrine activity in
the suprachiasmatic nucleus of the hypothalamus to regulate sleep/wake cycles [94]. The biological
conversion of serotonin into melatonin for induction of sleep highlights the potential for serotonin
turnover to alter sleep cycles.
The exact role of serotonin in sleep regulation is controversial. Serotonin levels are elevated in
most cortical areas during wakefulness and accordingly, SSRIs have been shown to cause insomnia,
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delay onset of rapid eye movement (REM) sleep, increase nighttime awakenings and reduce both
REM and slow-wave sleep [95]. SSRI-induced insomnia may be related to stimulation of the 5-HT2
receptors in the brain sleep centers, part of the serotonergic pathway that projects to the cholinergic
neurons of the lateral tegmentum, which are critical for inhibition and sleep maintenance [96,97]. High
serotonin levels during wakefulness and high activity in serotonergic neurons of the dorsal raphe
nucleus further contribute to serotonergic control of waking cortical activity [97].
3.4.2. Evidence Synthesis
Few studies have been conducted specifically to study SSRI effects on sleep following TBI.
The aforementioned three-group (sertraline, methylphenidate, placebo) RCT by Lee et al. found
methylphenidate to be better at reducing daytime sleepiness whereas sertraline provided no benefit
over placebo [30].
3.4.3. Commentary
It is logical that a nootropic stimulant can improve alertness; methylphenidate works by promoting
the release of dopamine from presynaptic terminals and preventing its reuptake by presynaptic
terminals [98]. The increased concentration of extraneuronal dopamine impacts the basal ganglia and
cortex promoting alertness and wakefulness. Of note, Sobanski et al. found that in adults with sleep
disturbance due to ADHD, methylphenidate improved sleep quality as well [99].
The complex mechanism of serotonin involvement in regulation of sleep underlies the diverse
side effects attributable to SSRI treatment. The utility of SSRIs as part of combination therapy to
treat post-TBI depressive symptoms while avoiding insomnia and sleep-cycle disruptions remains
an active area of investigation. Future well designed controlled cohort studies or RCTs of such
therapies are necessary to understand better drug interactions and risk profiles for different age groups,
comorbidities, professional responsibilities and support networks, and emotional resiliency in the
TBI population.
3.5. Anxiety Spectrum Disorders
3.5.1. Background and Pathophysiology
Anxiety symptoms following TBI may be due to a combination of neurotransmitter disruption
and neuronal dysregulation, psychological factors associated with trauma, and social consequences
from TBI. Symptoms range from subtle changes in mood and behavior to debilitating panic, agitation,
and agoraphobia, often most profound shortly following injury. As expected, preexisting psychiatric
conditions increase the risk of developing new anxiety disorders following injury [100,101]. At one-year
post injury for mild TBI, the new-onset anxiety disorders have been reported as follows: general anxiety
disorder 10%, PTSD 7.8%, agoraphobia 7.2%, social phobia 4.9%, panic 3.7%, and OCD 1.8% [102].
3.5.2. Evidence Synthesis
One open-label study and seven case reports investigated the use of SSRIs in post-TBI
anxiety spectrum disorders, including obsessive-compulsive disorder (OCD), panic disorder, and
emotional incontinence.
3.5.3. Obsessive-Compulsive Disorder (OCD)
SSRIs are the first-line treatment for OCD due to documented advantages over placebo [103,104].
Across three studies with 282 patients and a maximum follow-up period of 7.5 years, TBI was associated
with a 2.6-fold increase in relative risk of developing OCD [105]. In a 2002 case report Stengler-Wenzke
and colleagues reported on an 18-year-old man who sustained a TBI due to a motor vehicle accident
(MVA). Ten months after the initial trauma, the patient recovered normal neurological function but
reported compulsions, obsessions and impulsivity, scoring far above the threshold for clinical screening
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on the Yale-Brown Obsessive Compulsive Scale (YBOCS). His MRI showed multiple lesions affecting
the right ventrolateral prefrontal cortex, and single-photon emission computed tomography (SPECT)
imaging showed serotonin transporter density at two SDs below normal. After nine days of treatment
with 60 mg of fluoxetine/day the patient reported marked reduction of compulsions with decreased
YBOCS [51]. The fact that these studies suggest a similar role of SSRIs for TBI-induced OCD raises the
need for an RCT or at minimum a large controlled cohort study to evaluate their efficacy in modulating
post-TBI OCD development.
3.5.4. Panic Disorder
In the three aforementioned studies by van Reekum and colleagues, TBI was associated with
a 5.8-fold relative risk for developing panic disorder [105]. Similarly, a 2010 prospective cohort study
of 1084 individuals showed two-fold odds of developing panic disorder after TBI [102]. Damage to
the frontal lobes, in particular the ventral medial prefrontal cortex, which modulates fear response
in the amygdala, and/or direct compromise to the hippocampus and amygdala, are implicated in
the development of post-TBI panic and anxiety disorders [102]. In a case report Scheutzow et al.
described an individual suffering a panic attack during rehabilitation three months following TBI,
which negatively impacted lifestyle, employment, relationships, and increased risk of suicide. While
sertraline administration for two months improved mood and appetite symptoms, it did not lead to
full resolution of panic and anxiety symptomatology; in these refractory cases cognitive behavioral
therapy may be additionally indicated [46].
3.5.5. Emotional Incontinence
The true prevalence of emotional lability and/or incontinence following TBI is difficult to discern
due to high rates of concurrent neuropsychiatric sequelae e.g., depression and/or mania. Nahas et al.
report a case of emotional incontinence in a 21-year-old Caucasian man sustaining severe TBI after
motor vehicle ejection; at six months he continued to suffer from memory, impulse control and language
deficits as well as outbursts of inappropriate hysterical laughter; notably, administration of fluoxetine
20 mg/day decreased symptomatology in two days and resolved all symptoms within one week [44].
In another 56-year-old female TBI patient requiring bilateral frontal lobectomies who exhibited
labile irritability and spontaneous crying refractory to lithium carbonate, administration of sertraline
50 mg/day completely resolved her symptoms of emotional lability and depression [52]. Additionally,
two cases of post-TBI Kluver-Bucy syndrome—a mood disorder characterized by hypersexuality
and hyperorality due to medial temporal lobe and amygdala lesions—were successfully treated with
SSRI [47].
3.5.6. Commentary
In persons with TBI presenting with anxiety symptoms, pharmacotherapy using sertraline may
serve as effective adjuncts to behavioral modification and cognitive-behavioral therapy in treating
specific anxiety disorders, although few studies have been able to accurately measure the efficacy
following TBI due to frequent co-occurrence with depression [27,35]. Studies within the scope of this
review consist of case reports supporting the efficacy of SSRI in reducing anxiety following TBI, hence
results from post-TBI SSRI therapy are individual-based and dependent on the presenting symptoms.
3.6. Side Effects of SSRI Administration
3.6.1. Depression-Indicated Studies
The need for a comprehensive system of care is demonstrated by numerous case reports
outlining side effects associated with SSRIs in post-TBI depression. Patterson and colleagues describe
a 43-year-old man treated with fluoxetine following moderate TBI, who developed dysarthria and
speech block within one week as well as insomnia and needed supplemental trazodone [45]. Similarly,
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a 24-year-old man receiving sertraline for PTSD reported dystonia who was also administered
trazodone [50]. Spinella et al. describe a 42-year-old woman with a history of depression following mild
TBI who combined St. John’s Wort with buspirone and fluoxetine, leading to hypomania characterized
by insomnia, worsening memory, agitation and increasing depression [49]. Side effects in all cases
ceased upon discontinuing SSRI, underscoring the need for caution and mindful evaluation when
prescribing SSRIs with other psychotropic medications. In contrast, a 23-year-old TBI patient who
developed seizures after the TCA desipramine experienced resolution when switched to fluoxetine
and phenytoin [53]. A study of 10 mild to moderate TBI patients with depression found that Ham-D
and MMSE scores significantly improved after six weeks of treatment with the serotonin noradrenaline
reuptake inhibitor (SNRI) milnacipran, which does not inhibit CYP450 subtypes and therefore cause
fewer drug interactions compared to SSRIs [106].
3.6.2. Akathisia
Akathisia is defined as a feeling of inner restlessness resulting in the inability to remain still,
and the compulsion to move with observable restless movements. Hensley and colleagues describe
the case of a 22-year-old male with history of polysubstance abuse and PTSD who sustained TBI
with polytrauma after MVA [43]. The patient was started on sertraline 50 mg/day for anxiety and
depression and demonstrated extreme restlessness and anxiety two days into administration. Similar
restless symptoms occurred with administration of the SSRI paroxetine, further raising suspicion for
akathisia as an early adverse effect of serotonergic toxicity. Ultimately, a TCA was prescribed and
restlessness did not recur [43]. It is hypothesized that serotonergic toxicity occurred in this case due to
serotonergic inhibition of dopamine pathways. The mechanism of akathisia is not well understood
and may depend on drug metabolism through CYP450, serotonin receptor affinity and the selectivity
of the administered SSRI [107].
3.6.3. Sexual Dysfunction
A common barrier to treatment using SSRIs is the associated side effect of sexual
dysfunction. Mechanistically, serotonergic inhibition of excitatory mesolimbic dopaminergic pathways,
CYP450-mediated decreases in nitric oxide, and anticholinergic effects correlate with a 30%–50%
prevalence of sexual difficulties in patients using SSRI [108]. Dolberg and colleagues report that
15 of 17 TBI patients prescribed SSRIs showed improvement in sexual dysfunction with concurrent
administration of the 5-HT2A postsynaptic agonist mianserin, 10 of whom reached pre-injury levels of
sexual function [34]. Although isolated, this study underscores an important area of future research
regarding the potential for combination therapies utilizing the benefits of SSRIs following TBI if the
side effects are well controlled.
3.7. Post-Traumatic Stress Disorder (PTSD): Commentary and Implications
PTSD is a clinical syndrome characterized by reliving trauma, self-isolation and avoidance,
and hypervigilance in response to severe traumatic events. Clinically significant changes in arousal,
cognition and mood converge with the overlapping neuropsychiatric sequelae with mild and
moderate TBI [109]. PTSD is often associated with functional changes in the amygdala, hippocampus,
orbitofrontal, dorsomedial and dorsolateral prefrontal cortex [110]. Of these areas, the orbitofrontal,
dorsomedial, dorsolateral prefrontal cortex and the hippocampus are prone to axonal shearing
following TBI. Common neurobiological etiology supports an extensive overlap of symptoms including
sleep disturbance, cognitive impairment, depression and anxiety between TBI and PTSD [111].
The FDA-recommended treatment for PTSD includes the SSRIs sertraline and paroxetine based
on RCT evidence [112,113]. Fluoxetine, venlafaxine (SNRI, serotonin and norepinephrine reuptake
inhibitor) and prazosin (alpha-1 adrenergic receptor antagonist) have also shown promise in treating
PTSD [109,114,115]. For this reason, SSRI treatment of comorbid TBI and PTSD is important to
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guide physician care of the growing number of patients presenting with this complex constellation
of symptoms.
Of note, our review did not identify any RCTs or prospective studies targeting the efficacy and
utility of SSRI administration to treat symptoms specifically following TBI. While there is ample
evidence for SSRI use in treatment of PTSD, the lack of evidence-based trials for SSRI use in the
post-TBI population is troubling and should be a pressing focus of further studies. From the RCTs
discussed in our review, the threshold for conducting such a study in this population is reasonable and
within reach.
4. Discussion
The rising incidence of TBI, coupled with the increased survival after TBI (due to improvements
in medical management), creates a pressing need for further study into the best practices for managing
the psychiatric sequelae of TBI. This comprehensive review of the literature to date review investigated
the utility of SSRIs in treating a constellation of post-TBI cognitive, psychiatric and mental health
disorders. SSRIs are widely prescribed due to their efficacy, relatively selective mechanism of action,
and lower side effect profile compared to earlier antidepressants (e.g., monoamine oxidase inhibitors).
We aimed to consolidate the literature describing the effects of SSRI following TBI. It is our hope that,
by summarizing the state of the current knowledge base, we highlight the need for further research
toward generating guidelines for SSRI use specifically for treatment of TBI sequelae. Our goal is to
ensure that SSRIs are utilized and prescribed in the correct manner in order to optimize recovery
following TBI.
4.1. Limitations
This comprehensive review on the management of neuropsychiatric disorders following TBI
using SSRIs has demonstrated several important limitations. Due to the breadth of studies available,
we present our findings as an exploratory investigation without grading the level of evidence or
bias, which is a limitation of the current study. We also perform a small meta-analysis of disorders
sharing a common medication and a common endpoint, and in our literature search this was limited
to sertraline and the Ham-D, respectively. The small sample sizes of the RCTs and the open-label
trials have hampered the ability to provide definitive efficacy of SSRI in treating neuropsychiatric
deficits other than post-TBI depression. There is a lack of retrospective cohort studies on the topic,
which may bolster Class III evidence. Notably, in the current report we did not evaluate the effect of
SSRIs in the setting of and/or compared to other interventions such as cognitive behavioral therapy,
which warrants further study. These constitute relevant topics for future investigations in the manner
of a systematic review, which can be performed for specific medications, disorders and/or outcomes
using a more targeted approach and/or in greater depth.
Other pharmacotherapies including methylphenidate, dextroamphetamine, amantadine, and
tricyclic antidepressants are also being studied as part of pharmaco-rehabilitation for the improvement
of cognition, mood, and behavior in various TBI subpopulations [116–118]. Further, Van Waes and
colleagues highlighted through the expression of transcription factors that SSRIs might not only
influence depression and cognition, but also enhance the addition potential for methylphenidate when
used in combination [119]. Variations in time to follow-up after initial trauma, in addition to the
inability to clearly delineate treatment effects from the natural course of recovery, are also significant
limitations that can be overcome through using consistent outcome measures, standard follow-up
intervals, larger sample sizes, and systematic blinding of and/or control of cohorts to generate Class
I and II evidence. Lastly, the lack of a cognitive baseline prior to injury is a known limitation of the
accurate assessment of cognitive deficits attributable to trauma.
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4.2. Future Directions
While SSRIs are indicated as first-line treatment for a variety of psychiatric disorders both in
general and following TBI, the small effect sizes associated with SSRI treatment of post-TBI depressive
symptoms in a placebo-controlled setting demonstrates the need for further research, with standardized
patient populations and larger sample sizes. Potential deleterious effects of SSRIs on cognition
and agitation when used in conjunction with other psychotropic agents, along with its known side
effects and interactions with medications processed by CYP450, demonstrate the need for careful
cost-benefit assessment of SSRI use following TBI. Therefore, combined with the lack of current
consensus for improved outcomes, SSRIs remain a “potential option” rather than “effective treatment”
in the TBI population.
The heterogeneity of TBI, coupled with the broad effect of SSRIs on brain structure and function,
may require more selectively controlled populations and sophisticated trial methodologies in future
studies. We recommend a placebo-controlled longitudinal study with an extended follow-up period at
multiple time points, along with concurrent biomarker, neuroimaging and behavioral data to delineate
the true pharmacological effect of SSRIs in the TBI population. Absent such a study, SSRIs must
be applied on a case-by-case basis after careful attention is paid to the specific mood, behavioral,
and cognitive complaints of a given patient.
5. Conclusions
In the TBI population, RCTs on the efficacy of SSRIs have been few and limited to the specific
outcome measures of depression and cognition. SSRI use is generally associated with improvements in
depressive symptoms, although this effect may be a result of natural cerebral recovery. Conversely, SSRI
administration was not found to have any benefit on cognition; in fact, it may worsen cognitive function.
Pooled results using the Ham-D and sertraline showed a statistically significant mean decrease in
depressive symptoms as compared to placebo. SSRIs are broadly utilized in a number of case reports
and small open-label studies after TBI with general improvements in mood symptomatology, and
absent or negative effects for cognition and functional recovery. There is a dearth of studies focusing
on SSRI treatment effects for PTSD after TBI. Given the status of SSRI as a first-line therapy for
general PTSD, discernment of SSRI efficacy for TBI-induced PTSD represents an important direction of
future research. Parallel studies for other neurocognitive and neuropsychiatric domains are equally
important in assessing the potential of SSRIs to reduce mental health burden and optimize recovery
across TBI subpopulations.
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